SignaCor Therapeutics Raises €288k From Zinc in €1.1M Seed Round

Why It Matters

Securing early‑stage capital validates SignaCor’s novel epigenetic approach and accelerates a treatment for HCM, a condition with limited options. The investment also signals sustained investor confidence in European cardiovascular health tech, potentially shaping future therapeutic pipelines.

Key Takeaways

• SignaCor secures €288k from Zinc within €1.1M seed round
• Funding backs Phase 2a trial and HCM regulatory strategy
• European cardiovascular sector attracted over €136M in recent funding
• Cardiaza targets DNA methylation to reverse heart muscle fibrosis
• Discovery Spark accelerates life‑science startups via mentorship and investors

Pulse Analysis

Cardiovascular disease remains the leading cause of death in the UK, accounting for one in four fatalities, and the therapeutic gap for conditions like hypertrophic cardiomyopathy (HCM) is stark. SignaCor Therapeutics, a spin‑out from Queen’s University Belfast, is leveraging cutting‑edge epigenetic science to develop Cardiaza, a first‑in‑class drug that modulates DNA methylation to reduce fibrosis and restore cardiac function. By targeting the disease’s underlying pathology rather than merely managing symptoms, the company aims to improve both quality of life and long‑term survival for patients who currently have few effective options.

The recent €288k injection from Zinc, part of a €1.1 million seed round, provides the runway needed to launch a Phase 2a clinical trial and solidify the regulatory pathway. This capital infusion follows SignaCor’s triumph in Discovery Park’s Spark programme, which equips life‑science founders with industry mentorship, market insights, and direct investor access. The combination of scientific rigor and structured support accelerates the transition from laboratory proof‑of‑concept to patient‑centric data, positioning SignaCor to attract further series funding and strategic partnerships.

SignaCor’s financing reflects a broader surge of investment across Europe’s cardiovascular innovation ecosystem, which has seen more than €136 million poured into therapeutics, diagnostics, and AI‑driven tools in the past year. Such capital flows underscore investor confidence that novel, mechanism‑based therapies can deliver high‑value outcomes in a market hungry for breakthroughs. As programs like Discovery Spark continue to nurture early‑stage ventures, the region is poised to become a hub for next‑generation cardiac treatments, reshaping the therapeutic landscape and offering new hope to millions of patients.

Deal Summary

Belfast‑based healthtech startup SignaCor Therapeutics secured a €288k investment from venture capital firm Zinc, part of a €1.1 million seed round expected to close in April. The funding will support Phase 2a trial plans and regulatory strategy for its first‑in‑class treatment for hypertrophic cardiomyopathy. The deal was announced as part of Discovery Park’s Spark programme.